What Ibuprofen-Hemofarm Treats: Main Uses and Benefits

Ibuprofen-Hemofarm may be part of symptomatic management across three main domains, assisting with managing symptoms that interfere with daily functioning. Ibuprofen is used to reduce fever and relieve minor aches and pain from various sources.

The medication may assist with managing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort. It is applied across domains where additional symptomatic support is needed, typically when groups of symptoms appear suddenly or fluctuate. This use contributes to easing the overall symptom load when symptoms create noticeable physiological strain.

Ibuprofen-Hemofarm is commonly used across conditions presenting with acute episodes where symptoms related to systemic imbalance are present, such as an elevated body temperature (fever). This support contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability. Additionally, it is applied for symptoms linked to inflammatory or irritative states.

---

Quick Fact: Addressing Symptom Clusters

“It is used in areas where short-term symptom management is appropriate and may help patients cope more steadily with symptom fluctuations.”

Regulatory References

1. Ibuprofen: MedlinePlus Drug Information

Who Can and Cannot Use Ibuprofen-Hemofarm?

Eligibility for Ibuprofen-Hemofarm is defined by regulatory bodies through specific age, condition, and physiological restrictions. The medicine is generally permitted for use by adults and adolescents ge 12 years under standard labeled conditions, though older adults (geriatric patients) must use it with caution due to increased risk of adverse reactions. Children ge 6 months of age may be permitted to use the medicine under the guidance of a healthcare professional.

Contraindicated Populations

Use is absolutely contraindicated in patients with known hypersensitivity to Ibuprofen or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). It must not be used by individuals with active or recurrent peptic ulcer/gastrointestinal haemorrhage or a history of related perforation. Contraindications also apply to patients with severe heart failure (NYHA Class IV), severe renal impairment, severe hepatic impairment, and those in the third trimester of pregnancy (from 30 weeks gestation).

Restricted or Conditional Use

Use is restricted or requires special caution in populations with established cardiovascular disease, uncontrolled hypertension, or mild-to-moderate organ impairment (renal or hepatic). Use during the first and second trimesters of pregnancy is not recommended unless essential, while use during lactation is generally considered to present minimal risk.

Ibuprofen-Hemofarm, like all nonsteroidal anti-inflammatory drugs (NSAIDs), may interact with other medications, potentially increasing the risk of adverse effects or altering the effectiveness of either medicine. It is essential to consult your doctor or pharmacist before taking this product if you are using any other medicine.

Increased Risk of Bleeding

Concurrent use of Ibuprofen-Hemofarm with certain medications significantly increases the risk of severe gastrointestinal bleeding or hemorrhage. Avoid this combination unless strictly monitored by a healthcare professional:

• Other NSAIDs (including aspirin or acetylsalicylic acid) and cyclooxygenase-2 (COX-2) inhibitors.
• Anticoagulants (blood thinners), such as warfarin or Direct Oral Anticoagulants (DOACs), and antiplatelet agents.
• Corticosteroids (e.g., prednisone).
• Selective Serotonin Reuptake Inhibitors (SSRIs).

Reduced Efficacy of Other Medicines

Ibuprofen may reduce the effectiveness of medications used to manage blood pressure and other conditions. Close monitoring or dose adjustment may be necessary if you are taking:

Medicine Class	Potential Interaction
Diuretics (water pills) and ACE inhibitors/ARBs (for high blood pressure)	May reduce antihypertensive effect and increase the risk of kidney problems.
Lithium	Can increase the concentration of lithium in the blood, leading to toxicity.
Methotrexate	Can increase the concentration and potential toxicity of methotrexate.

Alcohol consumption while taking Ibuprofen-Hemofarm also increases the risk of stomach bleeding and ulcers.

How Ibuprofen-Hemofarm Works — Mechanism of Action

Direct Modulation of Prostanoid Synthesis

This mechanism involves the non-selective, reversible inhibition of Cyclooxygenase ( COX-1 and COX-2) enzymes, which are crucial for converting Arachidonic Acid into local mediators known as prostanoids. This primary action limits the production of key messengers, particularly Prostaglandin E2 ( PGE2), which underpins the drug's effect on physiological processes.

---

Downstream Regulation of Sensory Nerve Excitability

The subsequent reduction in local PGE2 concentration directly influences the excitability of peripheral sensory nerve endings. PGE2 normally makes them susceptible to potentiation by chemical signals; the drug's mechanism reduces this chemical potentiation, reducing the PGE2-mediated potentiation of nerve excitability. This adjustment in peripheral nerve sensitivity is the key physiological consequence that defines the mechanism's peripheral action.

---

Central Thermoregulatory Pathway Adjustment

The mechanism extends into the central nervous system, specifically targeting PGE2 synthesis within the hypothalamus, the body's internal control center for temperature. By suppressing the central production of PGE2 that occurs during fever, the drug initiates the hypothalamus set point adjustment.

Ibuprofen is primarily administered via the oral route, utilizing dosage forms such as tablets, capsules, or suspensions. Intravenous (IV) administration is also an officially approved route, typically reserved for pain and fever management in clinical settings.

Dosing is determined by the condition and clinical framework. For adult oral use, the standard dose range for non-prescription purposes is 200 mg to 400 mg per unit, with the absolute maximum daily intake limited to 1200 mg. Prescription regimens for inflammatory conditions utilize higher doses, ranging from 1200 mg up to a maximum daily dose of 3200 mg, which must be divided into smaller doses taken throughout the day.

The general frequency pattern requires doses to be separated by a minimum interval of 4 to 6 hours. Tablets should be swallowed whole with water, and it is recommended to take the medicine with food or milk if gastrointestinal discomfort is experienced during use. For liquid suspensions, accurate measurement is required after the bottle is shaken thoroughly. Use is generally designated as short-term for minor conditions; continuous long-term use is permitted only under medical supervision for chronic indications.

For specific populations, such as older adults and those with mild to moderate renal or hepatic impairment, guidelines suggest the use of the lowest effective dose for the shortest duration consistent with treatment goals. Pediatric dosing follows a weight-based regimen, typically measured in milligrams per kilogram (mg/kg).

Research Evidence / Overview of Studies

This section summarizes research evidence and provides an overview of clinical studies that evaluated the drug for its indicated use. The information presented is based on findings reported in peer-reviewed scientific literature.

---

Summary of Core Efficacy Studies

The primary goal of research was to examine the drug as a treatment for its approved indication (e.g., pain and inflammation). Studies typically focused on measured changes in pain scores, fever reduction, or inflammation markers over a defined period.

• Key Randomized Controlled Trials (RCTs):

  • Multiple RCTs reported changes in patient-reported symptoms (e.g., pain reduction measured by a standardized index) compared to placebo over short-term treatment courses.
  • Studies also evaluated the association between the drug and fever reduction compared to other control groups or baseline measures. Outcomes measured the degree and duration of temperature change.

• Comparative Studies:

  • Research often compared the drug's measured effects on pain and inflammation outcomes to other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Studies focused on evaluating the statistical difference in efficacy and the occurrence of adverse events among different NSAID formulations.

---

Evaluation in Specific Conditions

Research has explored the drug's effect in various conditions where pain and inflammation are primary symptoms.

• Acute Pain Management:

  • Studies examined the drug's use in relation to acute conditions such as post-operative pain, dental pain, and menstrual pain (dysmenorrhea).
  • These trials reported specific measured outcomes regarding pain intensity reduction and time to onset of effect.

• Fever Reduction (Antipyretic Use):

  • Clinical research in both adult and pediatric populations focused on evaluating the magnitude and duration of temperature reduction following administration. Evidence often suggests a dose-related response was observed.

Overall, the collected evidence from these studies evaluated the drug's effect on specific outcomes related to pain and inflammation across different patient groups. The consistency of these measured outcomes supports the drug's established indications.

Key Studies & References

1. Ibuprofen: A Review of its Pharmacological Properties and Therapeutic Efficacy
2. NICE Guideline: Non-steroidal anti-inflammatory drugs - Clinical guideline [CG176]

Storage and Disposal Conditions for Ibuprofen-Hemofarm

Official labeling requires this medicine to be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must avoid excessive heat above 40 C (104 F) to maintain stability.

Packaging and Safety

Storage must occur in the original container, which should be kept tightly closed. The product should not be used past the expiration date or if the blister packaging is torn or broken. A mandatory instruction for safety is to keep the medicine out of the sight and reach of children.

Disposal Requirements

Unused or expired medicinal product must be disposed of in accordance with local requirements. Regulatory guidelines explicitly state that medicines should not be thrown away via wastewater or household waste.